Squamous Cell Carcinoma Market

Market Overview:

The 7 major squamous cell carcinoma markets reached a value of US$ 693.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,402.7 Million by 2034, exhibiting a growth rate (CAGR) of 6.62% during 2024-2034.

The squamous cell carcinoma market has been comprehensively analyzed in IMARC's new report titled "Squamous Cell Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Squamous cell carcinoma refers to a type of cancer that occurs in the squamous cells, which are thin, flat cells that form the skin's surface, the lining of the hollow organs, and the respiratory as well as digestive tracts. This disease typically develops in areas exposed to the sun, such as the head, hands, neck, and lower legs, but it can also appear in other parts of the body. The most common symptom of the ailment is a scaly patch or a firm, red bump on the skin. Individuals suffering from this illness might also experience persistent soreness that may be painful, tender, or itchy; thickened, raised, or hardened skin regions; swollen lymph nodes; difficulty swallowing; changes in voice; etc. The diagnosis of squamous cell carcinoma involves a medical history assessment, a physical examination, and a biopsy. A healthcare professional will initially examine the affected area and check for any suspicious growths, sores, or changes in the skin's appearance. In some cases, various imaging studies, such as X-rays, CT scans, MRIs, etc., are also performed to detect the extent of the tumor and identify any metastases.

The increasing cases of prolonged exposure to ultraviolet (UV) radiation from tanning beds or the sun, which can lead to genetic mutations in the cellular DNA, are primarily driving the squamous cell carcinoma market. In addition to this, the rising incidences of several associated risk factors, including chronic wounds or inflammation, advancing age, a weakened immune system, etc., are further bolstering the market growth. Moreover, the widespread adoption of effective topical therapeutic agents, such as 5-fluorouracil and imiquimod, that can be directly applied to the affected site for disrupting cancerous cells is also acting as a significant growth-inducing factor. Besides this, the escalating utilization of cryotherapy, since it involves freezing the tumor with liquid nitrogen, thereby preventing the progression of the illness, is further creating a positive outlook for the market. Additionally, the emerging popularity of Mohs micrographic surgery to treat advanced and recurrent disease conditions, owing to its various advantages, like precise tumor mapping and high cure rates with minimal damage to the surrounding healthy tissue, is expected to drive the squamous cell carcinoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the squamous cell carcinoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for squamous cell carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the squamous cell carcinoma market in any manner.

Recent Developments:

• In March 2024, BeiGene, Ltd. announced that the U.S. FDA had approved TEVIMBRA (tislelizumab-jsgr) as a monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have received prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.
• In January 2024, INOVIO announced a clinical collaboration and supply agreement with Coherus BioSciences to assess the combination of INO-3112 and LOQTORZI (toripalimab-tpzi) as a potential treatment for patients with HPV16/18 positive oropharyngeal squamous cell carcinoma (OPSCC), a type of head and neck cancer also known as throat cancer.
• In January 2024, the FDA had approved DermaSensor, the first AI-powered tool to diagnose skin cancer, including squamous cell carcinoma, at the point of testing and noninvasively. DermaSensor is a wireless, handheld device that uses spectroscopy technology to examine lesions at cellular and subcellular levels and then assess those characteristics using an FDA-approved algorithm.
• In October 2023, Regeneron Pharmaceuticals, Inc. reported the first significant secondary objectives for an experimental regimen of PD-1 inhibitor Libtayo (cemiplimab) as a neoadjuvant monotherapy in stage II to IV resectable cutaneous squamous cell carcinoma.

Key Highlights:

• An estimated 1.8 million cases of squamous cell carcinoma are diagnosed in the U.S. each year.
• People with fair complexions, blue, green, or grey eyes, and a history of sun exposure are more likely to develop squamous cell carcinoma.
• Squamous cell carcinoma is more prevalent in men than in women.
• The incidence of squamous cell carcinoma increases with age and is highest in those aged 60 and up.
• The mortality rate of this condition is approximately 1% to 2%.

Drugs:

Libtayo is a fully human monoclonal antibody that targets the immunological checkpoint receptor PD-1 on T cells, developed utilizing Regeneron's unique VelocImmune technology. Libtayo has been demonstrated to inhibit cancer cells from suppressing T-cell activation by binding to PD-1. In the United States and other countries, Libtayo is indicated in select individuals with advanced basal cell carcinoma and advanced cutaneous squamous cell carcinoma.

Xevinapant is a potential first-in-class potent oral antagonist of IAPs (Inhibitor of Apoptosis Proteins). In preclinical tests, xevinapant restores cancer cells' sensitivity to apoptosis, depriving them of one of their primary resistance mechanisms. As the most clinically advanced IAP antagonist, xevinapant has demonstrated efficacy in combination with chemoradiotherapy (CRT) in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (LA SCCHN), with a clinically significant and long-lasting clinical benefit over CRT alone.

PRV111 is a topical patch that delivers and retains high concentrations of chemotherapeutic drug in the primary tumor and surrounding lymph nodes. When applied to a tumor, PRV111 releases and retains cisplatin-loaded particles, resulting in a significant reduction in tumor size and increased levels of tumor-infiltrating lymphocytes without the systemic side effects associated with intravenous cisplatin (nephrotoxicity and neurotoxicity).

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the squamous cell carcinoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the squamous cell carcinoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current squamous cell carcinoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the squamous cell carcinoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the squamous cell carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the squamous cell carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of squamous cell carcinoma across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of squamous cell carcinoma by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of squamous cell carcinoma by gender across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of squamous cell carcinoma by type across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with squamous cell carcinoma across the seven major markets?
• What is the size of the squamous cell carcinoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of squamous cell carcinoma?
• What will be the growth rate of patients across the seven major markets?
   

Squamous Cell Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for squamous cell carcinoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the squamous cell carcinoma market?
• What are the key regulatory events related to the squamous cell carcinoma market?
• What is the structure of clinical trial landscape by status related to the squamous cell carcinoma market?
• What is the structure of clinical trial landscape by phase related to the squamous cell carcinoma market?
• What is the structure of clinical trial landscape by route of administration related to the squamous cell carcinoma market?